Background Only a limited number of reports have documented zero mortality in consecutive pancreaticoduodenectomy series. The aim of this study is to review and verify our management aiming to eliminate mortality after pancreaticoduodenectomy. Methods Three hundred and sixty-eight consecutive patients undergoing pancreaticoduodenectomy between 2002 and 2015 were retrospectively reviewed. During this period, in order to enhance the safety of pancreaticoduodenectomy, we have used a consistent strategy consisting of early ligation of the inferior pancreatoduodenal artery, mucosal sutureless pancreaticojejunostomy combined with external pancreatic duct stenting, conditional two-stage pancreaticojejunostomy, jejunal decompression using tube jejunostomy, application of an omental flap to cover the stump of the gastroduodenal artery, and careful postoperative drain management. Results Major postoperative complications (ClavienDindo grade ≥ IIIa) occurred in 20 patients (5%). Grade A/B/C pancreatic fistula was observed in 49/29/4 patients (13%/8%/1%), respectively. Reoperation and readmission was necessary in five and four patients (1% and 1%), respectively. There was no in-hospital or 90-day mortality. Conclusions To achieve zero mortality in pancreaticoduodenectomy, it is crucial to incorporate various strategies to minimize the degree of surgical invasiveness and the damage caused by pancreatic fistula with a meticulous approach to perioperative management.
Introduction
Pancreaticoduodenectomy (PD) is the only surgical treatment providing the possibility of cure for patients with periampullary malignant tumors. In addition, it has recently been used to treat other diseases involving the pancreatic head, duodenum, and distal common bile duct. Despite advances in imaging and surgical instrumentation, and better preoperative patient selection and postoperative care, PD is one of the most complex procedures in gastroenterological surgery, and failure of the pancreatic anastomosis, intra-abdominal hemorrhage, and sepsis are still major issues that can result in postoperative mortality. Recently reported mortality rates after PD have decreased to less than 6% in high-volume centers [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , but are seldom zero. Although achievement of zero mortality in PD series continues to be a sought-after goal, only a limited number of reports have documented zero mortality in consecutive PD series [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Since October 2002, in order to enhance the safety of PD, we have implemented a consistent strategy consisting of early ligation of the inferior pancreaticoduodenal artery (IPDA) [20] , mucosal sutureless pancreaticojejunostomy (PJ) combined with external pancreatic duct stenting [21] , conditional two-stage PJ, jejunal decompression using tube jejunostomy [22] , application of an omental flap to cover the stump of the gastroduodenal artery, and careful postoperative drain management. We did not experience a single case of mortality throughout this period. Here we review the postoperative course of 368 consecutive patients who have undergone PD according to our strategy.
Methods

Patients
Between October 2002, when one of our group (S.K.) became head of the division, and December 2015, 368 consecutive patients underwent PD at our institution, and were the subjects of the present study. The study protocol was approved by the medical ethics committee of Juntendo University School of Medicine. Data collection and analysis were performed in accordance with our institutional guidelines, and the ethical standards of the Helsinki Declaration of 1975.
Preoperative evaluation and management
Preoperative workup for evaluation of patients' general comorbidity and tolerability was performed systematically, and routinely included serum and urine laboratory tests, chest and abdominal X-ray examinations, exercise electrocardiography, and pulmonary function tests. Preoperative percutaneous transhepatic biliary drainage and/or endoscopic retrograde biliary drainage were performed to decompress the biliary tree for relief of obstructive jaundice and/or treatment of cholangitis. All patients received preoperative intravenous antibiotics as prophylaxis for surgical-site infection.
Operative procedure All 368 PDs were performed by two surgeons (S.K. and Y.I.). Our standard surgical procedures for PD have been described previously [20] [21] [22] . All the patients underwent standard PD uniformly. After laparotomy, thorough abdominal exploration and a Kocher maneuver were conducted. In patients with periampullary malignant neoplasms, lymph node dissection was performed routinely around the common hepatic artery, porta hepatis, celiac axis, and portocaval and retropancreatic areas. Shortsegment venous involvement was managed by en bloc resection and venous reconstruction if necessary. In the approach for early ligation of the IPDA [20] , the portal trunk and superior mesenteric vein were encircled with tape. By providing leftward traction on the two tapes, the tissue and branch arteries arising from the IPDA were serially clamped, divided, and stitch-ligated before ligation of the inferior pancreaticoduodenal veins.
Reconstructions were performed according to a modified Child method with an isoperistaltic limb of the jejunum in a retrocolic manner; an end-to-side PJ, end-to-side hepatojejunostomy 20 cm distal to the PJ, an antecolic end-to-side double-layer gastrojejunostomy 40 cm downstream from the hepatojejunostomy, and Braun jejunojejunostomy. Prophylactic drains were routinely placed around the PJ and dorsal to the hepatojejunostomy. For decompression of the jejunal loop, a tube jejunostomy was created using a 16-Fr silicone tube (Fuji Systems Corporation, Tokyo, Japan). The tube was placed into the jejunal lumen from the stump side of the jejunam, via PJ, to hepatojejunostomy, and the opposite side of the tube was exteriorized through the abdominal wall [22] . In addition, the greater omentum, with a preserved blood supply, was placed behind the PJ and fixed to the lesser omentum to cover the stump of the gastroduodenal artery. No pancreatogastrostomies were performed in this series.
An end-to-side PJ was constructed in a mucosal sutureless manner combined with pancreatic duct stenting [21] . A row of non-absorbable stitches was placed in two layers between the jejunal seromuscular layer and the pancreatic parenchymal layer. A transanastomotic pancreatic duct tube using 4-13.5-Fr, 65-cm lengh polyvinyl chloride tube (Sumitomo Bakelite, Tokyo, Japan) matching the diameter of the main pancreatic duct was used for external drainage of pancreatic secretion. The pancreatic duct tube was passed into the jejunal lumen, brought out externally at the stump side, and exteriorized through the abdominal wall.
PJ was performed in a two-stage manner in patients with a normal main pancreatic duct and/or soft pancreas texture because the occurrence of clinically significant postoperative pancreatic fistula is more likely in such patients [23] . At the first operation, a pancreatic tube was inserted into the main pancreatic duct, and a posterior row of sutures was placed between the seromuscular layer of the jejunum and the pancreatic parenchyma. An incomplete row of sutures was also placed anteriorly, and the end of the pancreatic tube was brought out of the abdominal cavity without passing through the jejunal loop. A decompressive jejunostomy tube was placed in the same way as that for one-stage PJ. At the second operation, performed approximately 3 months later, we first conducted careful dissection around the fistula of the external pancreatic tube and exposed it from the skin to the anterior wall of the pancreas. A new pancreatic tube was inserted into the main pancreatic duct and the other end was inserted into the jejunal lumen through a small opening and brought out of the jejunum through the route of the decompressive jejunostomy tube. The PJ was completed with an additional anterior row of sutures.
Postoperative care
In the immediate postoperative period, all patients were managed in the intensive care unit. Active ambulation was promoted on the following day, and if the patient showed good recovery, the nasogastric tube was removed. Following the release of gas, oral intake was permitted and increased if the patient was able to tolerate it. However, if the patient showed signs of pancreatic fistula or delayed gastric emptying, initiation of oral feeding was decided according to the patient's condition and amount of drainage fluid. Total parenteral nutrition and/or prophylactic octreotide was not used routinely. The drain at the hepatojejunostomy was removed progressively from postoperative day (POD) 7 if no bile leakage was present. We routinely measured the amylase value in the fluid discharged through the drainage tube placed at the PJ. Drains placed around the PJ were removed progressively from POD 10 if there was no pancreatic fistula or other intra-abdominal complication. The drains were maintained for longer if patients had high drain amylase activity, copious fluid output or effluent with an unfavorable appearance (dark brown, greenish, milky or murky). The drains around the PJ remained placed until the patient had no apparent clinical manifestations suggestive of infection, no intra-abdominal cavity around the PJ containing leaked pancreatic juice or abscess, and formation of a fixed drainage route along the drains. Suspected pancreatic fistula was managed by antibiotics selected on the basis of susceptibility of bacteria isolated from drain fluids. If needed, supplementary parenteral nutritional support, use of somatostatin analogues, image-guided percutaneous drainage and, rarely, surgical exploration with wide peripancreatic drainage or repair of the PJ was performed. The patient was discharged with a decompressive jejunostomy tube and pancreatic duct tube in situ. The two tubes were removed in the outpatient clinic 8 weeks after PD. In cases of twostage PJ, the two tubes remained in place until the second operation. At the second operation, both tubes were replaced with new ones, and at 8 weeks after the second operation the tubes were removed in the outpatient clinic.
Postoperative complications were graded according to the Clavien-Dindo classification [24] , which has been validated for pancreatic surgery [25] . Pancreatic fistula and delayed gastric emptying were graded according to the International Study Group of Pancreatic Fistula criteria and the International Study Group of Pancreatic Surgery criteria, respectively [26, 27] . In-hospital and 90-day mortality were assessed.
Statistical analysis
Categorical variables were compared using a v 2 test. Continuous variables were expressed by median and range or mean and standard deviation, and compared using the Mann-Whitney U-test or a two-sample Student's t-test, respectively. P-values less than 0.05 were considered statistically significant. Statistical analyses were carried out using SPSS version 20.0 (SPSS, Chicago, IL, USA).
Results
A total of 368 patients, including 59 undergoing twostage PJ, underwent PD during the study period. Median follow-up period was 57 (range, 6-108) months. We selected one-stage PJ in those with dilated pancreatic duct and hard pancreas (n = 179), and two-stage PJ in patients with normal pancreatic duct and soft pancreas (n = 54). Among cases with normal pancreatic duct or soft pancreas (n = 135), two-stage PJ was performed in five patients in consideration of their comorbidity. Demographic and preoperative details are summarized in Table 1 . There were 239 male (65%) and 129 female (35%) patients with a median age of 67 years (range, 26-92 years). There were 25 patients (7%) aged over 80 years and 154 patients (42%) aged over 70 years. In 118 patients (32%), American Society of Anesthesiologists grade was grade III. Preoperative biliary drainage for decompression of biliary obstruction was performed in 194 patients (53%). Table 2 shows the operative and pathology data. The median operation time was 559 min and the median blood loss was 290 ml. Combined superior mesenteric vein and portal vein resection was performed in 14 patients (4%) due to vascular invasion of the tumor. Seven patients (2%) received perioperative blood transfusions. The procedure was performed for pancreatic cancer in 161 patients, ampullary cancer in 60, bile duct cancer in 49, intraductal papillary mucinous neoplasm in 47, neuroendocrine tumor in 16, duodenal cancer in 13, and other causes in 22.
Postoperative outcomes
The postoperative outcomes of the study cohort are detailed in Table 3 . In cases of two-stage PJ, perioperative factors and complications of the first operation were described. The median length of drain maintenance in patients with one-stage PJ and two-stage PJ was 23 and 29.5 days, respectively. In most of the patients who had drain placement for longer than 21 days, an amylase content of drain fluid on or after POD 3 did not reach greater than three times the upper normal serum value, therefore, these patients were not categorized as having pancreatic fistula. The reasons for prolonged drain placement in these cases were positive bacterial culture of drain fluid, copious fluid output or effluent with an unfavorable appearance, without apparent clinical signs of infection. Major complications (Clavien-Dindo grade ≥ IIIa) occurred in 20 patients (5%). Delayed gastric emptying was the most common complication, followed by development of a postoperative pancreatic fistula. Reoperation was necessary in five patients (1%). Reasons for reoperation were: re-do PJ for intractable pancreatic fistula (n = 2), re-insertion of a pancreatic duct stent (n = 1), postoperative hemorrhage not related to pancreatic fistula (n = 1), and bile leakage (n = 1). Four patients (1%) were readmitted for relapse of pancreatic fistula (n = 3) and pancreatitis of the remnant (n = 1). There was no in-hospital or 90-day mortality in this series.
In patients undergoing two-stage PJ, the median interval between PD and the second operation was 111 days (range: 73-331 days). The second operation for two-stage PJ was not performed in two patients in whom multiple liver metastases from pancreatic cancer appeared in the interval. The median operative time and median blood loss in the second operation was 135 min (range, 85-268 min) and 20 ml (range, 5-120 ml), respectively. No patient needed blood transfusion in the second operation. Major postoperative complication (Clavien-Dindo grade > IIIa) was not observed. Grade A and B pancreatic fistula occurred in eight (14%) and three (5%) patients after the second operation, respectively. The median length of postoperative hospital stay was 16 days (range, 8-150 days) and there was no readmission.
Discussion
Recent advances in surgical techniques and adequate management of postoperative complications have led to improved clinical outcomes of PD, and the mortality following PD has decreased to below 6% [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] (Table 4) . However, zero mortality in large series of consecutive cases is rarely accomplished. Only a few reports have documented no mortality in consecutive series of PD cases [11] [12] [13] [14] [15] [16] [17] [18] [19] (Table 5) . Therefore, efforts to prevent operative mortality after PD should be maintained. Since October 2002 we have established a standardized protocol of perioperative management in order to eliminate mortality, and have not experienced a single case of mortality throughout this period. In contrast, before October 2002 we performed 58 cases of PD for 3 years. In the period, one patient died 56 days after surgery because of intraabdominal bleeding associated with pancreatic and biliary leakage, and the postoperative mortality rate was 1.7%. To our knowledge, 368 consecutive PD cases without mortality is the largest such series to have been reported so far. The complication most likely leading to operative mortality following PD is pancreatic fistula. An uncontrolled pancreatic fistula resulting from PJ failure can be catastrophic, resulting in delayed gastric emptying, intraabdominal abscess formation, or hemorrhage due to major 
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3 (1) 3 (1) vessel erosion, theoretically increasing in-hospital mortality by as much as three-fold [28] . In order to reduce the risk of PF and minimize the damage, various methods have been attempted and controversies still exist. Of these, optimal drain management in PD remains one of the largest issues. We routinely place three drains around the PJ and keep them in situ for no less than 10 days after PD. Removal of these drains is only performed after confirming that patients have no apparent clinical manifestations suggestive of infection, no intra-abdominal cavity containing leaked pancreatic juice or abscess, and a fixed drainage route around the drains. This approach differs markedly from current trends in drain management after PD in that it represents an active attempt to explore the safety and efficacy of abandoning routine prophylactic drainage or employing early drain removal. Several case series [7, 8, 10, [29] [30] [31] and a recent randomized controlled trial [32] have suggested that it might be possible to safely abandon routine prophylactic drainage after pancreatic resection. However, the reported mortality in those studies was by no means zero. Moreover, another randomized controlled trial has strongly supported the conclusion that primary operative drainage at the time of PD should not be abandoned [6] . In that study, elimination of intraperitoneal drainage in all cases of PD increased the severity and frequency of complications and contributed to a 4-fold increase in mortality from 3% to 12% [6] .
Instead, early drain removal in PD has been supported by several studies in view of a lower rate of postoperative complications and a resulting reduction in hospital stay and costs. Kawai et al. [33] assessed 104 consecutive patients undergoing pancreatic head resection and concluded that removing the drain on POD 4 rather than on day 8 reduced the incidence of complications. Bassi et al. [34] evaluated 114 patients with a low prior probability of pancreatic fistula, including only patients with drain amylase levels of <5,000 U/l. They concluded that the drain could be safely removed on POD 3. Moreover, delayed removal of the drains (after POD 5) led to a higher complication rate and increased both hospital stay and costs. Ven Fong et al. [5] reported that the risk of PF after PD was less than 1% if the POD 1 drain amylase level was lower than 600 U/l and proposed that in this group, which comprised more than 60% of patients, drains should be removed on POD 1.
In contrast to these results, other studies have concluded that the early dynamic postoperative changes in drain volume and amylase concentration are not clearly correlated, the later development of a clinically significant postoperative pancreatic fistula making this approach problematic [35, 36] . A considerable proportion of patients with pancreatic fistula did not initially demonstrate an amylase-rich effluent. These patients had significantly worse outcomes, potentially leading to mortality. We have also experienced some patients who show late onset of a clinically significant postoperative pancreatic fistula. Therefore, routine late drain removal has become our standard management for alleviating this rare but potentially lethal complication. Nevertheless, during the study period, three of our patients were re-admitted due to relapse of pancreatic fistula. We agree that in some patients unnecessary long-term drain placement could result in an increased rate of intra-abdominal infections by providing a route for ascending infections, thus increasing the period of hospitalization and costs. However, at the same time, we strongly believe that prolonged drain placement could protect a few patients from devastating late-onset PF and operative mortality. Needless to say, prevention of mortality and safe patient discharge are far more important priorities for surgeons than saving costs. Trede [19] 118
The adverse events associated with pancreatic fistula formation are mainly related to the digestive power of pancreatic juice, which is activated and strengthened by the enteric contents, and also secondary infection [37] . After PD, pancreatic juice wells out from not only the main pancreatic duct but also the transected surface of the pancreas. Despite several attempts, neither modification of the surgical technique nor improvements of peri-PD management strategies have been effective in reducing such exudation of pancreatic juice. Therefore, to minimize post-PD morbidity and mortality, it might be more reasonable to adopt a strategy to prevent leaking pancreatic juice from becoming activated than to prevent leakage from the pancreatic stump per se. Conditional two-stage PJ is generally an uncommon practice, but several studies from Japan have reported its efficacy [16, [38] [39] [40] [41] and we also favor this strategy. We use this procedure for patients with a narrow main pancreatic duct and/or a soft pancreas texture, who are at higher risk of PF [23] . Two-stage PJ is theoretically effective for preventing pancreatic juice enzymes from becoming activated by enteric contents after the first operation. At the second-look operation, it was easy to approach the site of pancreatic fixation along the pancreatic tube. After placing a new tube in the main pancreatic duct, inserting the other end into the jejunum, and bringing it out of the jejunal wall, the rough anastomosis between the scar tissue around the pancreatic duct and the jejunal wall was sufficient for securing the anastomosis. Even if the anastomosis is insufficient and pancreatic fistula occurs, the infection will be localized around the anastomosis site and cause no serious problem. Although a two-stage operation forces patients to endure a longer postoperative period with tubes on the abdomen, two-stage PJ appears to be effective for minimizing pancreatic juice-related adverse events and consequently reducing postoperative mortality, especially in high-risk patients with a narrow pancreatic duct and/or soft pancreas.
In addition, jejunal decompression using tube jejunostomy is also our routine practice, with the aim of preventing leaking pancreatic juice from becoming activated [22] . Although the pancreatic juice in the main pancreatic duct is completely removed through the pancreatic tube and does not become activated, that welling from the transected surface of the pancreas is activated by digestive or bile juice that may leak through a small opening in the jejunal wall. As a consequence, the risk of erosion resulting from activated pancreatic enzymes is not obviated, and this increases the risk of suture failure. Postoperatively, many patients experience prolonged inhibition of coordinated bowel activity, which causes accumulation of secretions and gas in the jejunal loop, resulting in an increase of intraluminal pressure. This prolonged inhibition can take days or weeks to resolve, and often results in leakage of the contents of the jejunal loop onto the cut surface of the pancreas. Jejunal decompression is expected to reduce this risk. In our series, mean daily volume from decompressive jejunostomy in each patient was 10-90 ml.
For the purpose of avoiding intra-abdominal hemorrhage after PD caused by a pancreatic fistula and/or intraabdominal infection, it is important to protect the dissected splanchnic vessels from exposure to leaked pancreatic juice. The greater omentum, which has an excellent blood supply, has impressive capabilities for absorption of fluid, adhesion formation, neovascularization, and defense against infection, accelerating the healing of tissue defects [42] . Accordingly, we preserved the blood supply of the greater omentum and placed it behind the site where the pancreas was fixed to the jejunum. This technique protects the stumps of the gastroduodenal artery or other arteries from exposure to pancreatic juice when the juice leaks from the pancreatic cut surface, and helps to prevent pancreatic fistula and bleeding from the major arteries [43, 44] .
Increased intraoperative blood loss and the need for blood transfusion have been reported to be significant predictive risk factors for complications of PD [45] . In standard PD, bleeding arises mainly from congestion of the pancreas head because any portal venous branches need to be divided from the portal vein prior to ligation of the IPDA. Therefore, it is suggested that early ligation of the IPDA before ligation of the inferior pancreaticoduodenal veins is an effective technique for minimizing intraoperative blood loss during PD. Our previous study [20] and other studies [46] [47] [48] reported that early ligation of the IPDA not only reduced intraoperative blood loss during PD but also alleviated postoperative morbidity and mortality. In the present case series, only seven patients (2%) received perioperative blood transfusions. Thus, early ligation of the IPDA may also have contributed to the zero mortality observed in the present case series.
Median length of postoperative hospital stay of the present series was quite long at 46 days (Table 3) . Because patients were discharged with a decompressive jejunostomy tube and pancreatic duct tube in situ, they needed to learn self-management of the tubes before discharge, resulting in additional days of postoperative hospital stay. In addition, postoperative patients tended to desire continuation of hospitalization until their condition was fully recovered, to which we have a relatively tolerant attitude.
In conclusion, the greatest priority when performing PD, one of the most invasive operative procedures in the field of abdominal surgery, should be accorded to prevention of operative mortality. Shortening of the hospital stay and reduction of costs have much lower priority. The results we have obtained in this series indicate the safety and justification of our strategy for PD. We suppose that the keys and significant features among our strategies to achieve zero mortality following PD are two-stage PJ and careful drain management. Both methods may force unnecessary prolonged care period for some patients, but can prevent operative mortality resulting from devastating pancreatic fistula especially in high-risk patients. To achieve zero mortality in pancreaticoduodenectomy, it is crucial to incorporate various strategies to minimize the degree of surgical invasiveness and the damage caused by pancreatic fistula with a meticulous approach to perioperative management.
